News & Resources
AAIC 2020 Day Two Summary
By Associate Biomarker Scientist Hiba Kazmi A summary of interesting talks which we attended on Day 2 of the AAIC. In particular, there was a focus on incorporating imaging with a range of other biomarkers (for example blood plasma and retinal) and also translating AD biomarkers for clinical application.
AAIC 2020 Day One Summary
By Biomarker Scientist Niccolo Fuin Lots of biological motivation on AD progression and molecular biomarkers. Most interesting session for me was: “Development Of New Models And Analysis Methods: Novel Imaging Analysis“ in which Pablo F.
Medical Image Understanding and Analysis (MIUA) Publication 2020
Transfer learning for brain segmentation Pre-task selection and data limitations
Schizophrenia International Research Society (SIRS) 2020 Poster
Actigraphic Monitoring of Sleep-Wake Cycle in Schizophrenia Outpatients
Receiving a Long-Acting Injectable Antipsychotic: Feasibility and Initial
Results From a Prospective RCT
The rise of digital health in the times of COVID-19
The COVID-19 pandemic has put considerable strain on the healthcare services across the globe and is impacting clinical development across many therapeutic areas, as many resources are being diverted to fighting the pandemic.
Quantitative amyloid PET in Alzheimer’s disease: the AMYPAD prognostic and natural history study
The Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) Prognostic and Natural History Study (PNHS) aims at understanding the role of amyloid imaging in the earliest stages of Alzheimer’s disease. AMYPAD PNHS adds (semi-)quantitative amyloid PET imaging to several European parent cohorts to predict AD-related progression as well as address methodological challenges in amyloid PET.
73-80 of 155 results